Piyush Jain

Piyush Jain

Auto-generated profile, based on publicly available information

Piyush Jain

Laboratory for Intestinal Neuroimmune Interactions, Translational Research Center for Gastrointestinal Disorders, KU Leuven Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2021 in Nature
Verified
Journal Article
Open access
PDF file
JAJavier Aguilera-Lizarraga
Javier Aguilera-Lizarraga
MFMorgane V. Florens
Morgane V. Florens
MVMaria Francesca Viola
Maria Francesca Viola
PJPiyush Jain
Piyush Jain
LDLisse Decraecker
Lisse Decraecker
GBGuy E. Boeckxstaens
Guy E. Boeckxstaens
Up to 20% of people worldwide develop gastrointestinal symptoms following a meal1, leading to decreased quality of life, substantial morbidity and high medical costs. Although the interest of both the scientific and lay communities in this issue has increased markedly in recent years, with the worldwide introduction of gluten-free and other diets, the underlying mechanisms of food-induced abdominal complaints remain largely unknown. Here we show that a bacterial infection and bacterial toxins can trigger an immune response that leads to the production of dietary-antigen-specific IgE antibodies in mice, which are limited to the intestine. Following subsequent oral ingestion of the respective dietary antigen, an IgE- and mast-cell-dependent mechanism induced increased visceral pain. This aberrant pain signalling resulted from histamine receptor H1-mediated sensitization of visceral afferents. Moreover, injection of food antigens (gluten, wheat, soy and milk) into the rectosigmoid mucosa of patients with irritable bowel syndrome induced local oedema and mast cell activation. Our results identify and characterize a peripheral mechanism that underlies food-induced abdominal pain, thereby creating new possibilities for the treatment of irritable bowel syndrome and related abdominal pain disorders.

7 September 2020 in Heart
Verified
Conference Paper
Open access
PDF file
MHMei-Lian Hoe
Mei-Lian Hoe
SQShahzad Qayyum
Shahzad Qayyum
DADominique Auger
Dominique Auger
NDNizar Damani
Nizar Damani
AGAnne Griguer
Anne Griguer
JSJoban Sehmi
Joban Sehmi
Introduction Computer tomography coronary angiography (CTCA) can be performed with improved image quality and at lower radiation dose when heart rate is lowered to less than 60 beats per minute (bpm). In our centre intravenous Metoprolol is administered on the CT table targeting a heart rate below 60 bpm. The aim of this audit was to assess the efficacy of intravenous beta-blockade to achieve optimal heart rates in patients undergoing CTCA. Methods We carried out a retrospective case note review of all patients undergoing CTCA between 1 – 30 November 2018. Scanning was performed using a 320-detector row scanner with prospective gating (Toshiba Aquilon One). Data collected included attending radiologist/cardiologist, dose of Metoprolol, heart rate at time of image acquisition and baseline patient characteristics. Results Case notes of 131 consecutive patients referred for CTCA were reviewed. The mean heart rate achieved was 61.7 bpm (range 30–130 bpm). The average administered dose of metoprolol was 15.5 mg (range 0–60 mg). 51% of patients achieved a heart rate less than 60 bpm at the time of scanning. For patients achieving target heart rates below 60 bpm the average dose of metoprolol was 9.3 mg, and 22.4 mg for those with heart rates greater than 60 bpm at the time of image acquisition. Conclusion Routine administration of intravenous beta-blocker peri-procedure fails to achieve optimal heart rate control in approximately half of all patients undergoing CTCA. Alternative protocols including pre-treatment with a short course of oral beta-blockers should be considered.